Metacrine MTCR shares are trading higher on Monday after multiple firms initiated coverage on the stock with a bullish rating.

Metacrine is a clinical-stage biopharmaceutical company focused on discovering and developing differentiated therapies for patients with liver and gastrointestinal diseases.

Metacrine shares traded up 6.83% to $10.86 on Monday at the time of publication. The stock has a 52-week high of $16.19 and a 52-week low of $9.06.